mesalamine has been researched along with tofacitinib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Awasthi, BP; Chaudhary, P; Jeong, BS; Karmacharya, U; Kim, JA; Kim, YE; Lee, IH; Nam, TG; Regmi, SC | 1 |
| Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R | 1 |
| Siegmund, B; Sonnenberg, E | 1 |
| Bosdelekidou, EE; Economopoulos, KP; Iliopoulou, SM; Kokkinidis, DG; Kousoulis, AA; Tassos, AG; Texakalidis, PT | 1 |
| Battat, R; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Parker, CE; Sandborn, WJ | 1 |
| Huang, E; Patel, S; Rubin, DT; Shaffer, SR | 1 |
2 review(s) available for mesalamine and tofacitinib
| Article | Year |
|---|---|
Emerging treatments for ulcerative colitis: a systematic review.
Topics: Andrographis paniculata; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Piperidines; Plant Extracts; Pyrimidines; Pyrroles; Remission Induction | 2017 |
Innovations in Oral Therapies for Inflammatory Bowel Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Indans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Mesalamine; Oxadiazoles; Phosphodiesterase Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Triazoles | 2019 |
4 other study(ies) available for mesalamine and tofacitinib
| Article | Year |
|---|---|
Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions.
Topics: Acetamides; Animals; Cell Adhesion; Colitis; Dose-Response Relationship, Drug; Interleukin-6; Molecular Structure; Rats; Structure-Activity Relationship; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2021 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendectomy; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Fecal Microbiota Transplantation; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Leukapheresis; Mercaptopurine; Mesalamine; Methotrexate; New Zealand; Pediatrics; Piperidines; Proctocolectomy, Restorative; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor-alpha | 2015 |
Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Integrins; Janus Kinases; Mercaptopurine; Mesalamine; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Tumor Necrosis Factor-alpha | 2016 |
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Cost-Benefit Analysis; Deprescriptions; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Infliximab; Markov Chains; Mesalamine; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years | 2021 |